Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austco HealthcareASX:AHC 56 3-Year EBITDA Growth Rate is 35.70% as of Dec. 2025, which is 94% above its 10-year median of 18.40. GuruFocus rates ASX:AHC with a GF Score™ of 56/100 and a GF Value™ of A$0.36 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Austco Healthcare ranks better than 81.5% on this metric.
During the past 12 months, Austco Healthcare's average EBITDA Per Share Growth Rate was 12.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 35.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Austco Healthcare was 81.70% per year. The lowest was -12.60% per year. And the median was 18.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Austco Healthcare 3-Year EBITDA Growth Rate Related Terms
ASX:AHC vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Austco Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austco Healthcare 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austco Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Austco Healthcare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 35.70% mean?
Austco Healthcare (ASX:AHC) has a 3-Year EBITDA Growth Rate of 35.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Austco Healthcare and its competitors. This is 94% above median its historical median of 18.40. According to the industry distribution chart, Austco Healthcare ranks #128 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 18.5%.
Is Austco Healthcare's 3-Year EBITDA Growth Rate too high?
Austco Healthcare's current 3-Year EBITDA Growth Rate of 35.70% is 94% above median its 10-year median of 18.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Austco Healthcare's value of 35.70% is 335.4% above this industry median. Based on the distribution chart, Austco Healthcare ranks #128 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Austco Healthcare has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austco Healthcare's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Austco Healthcare ranks #128 out of 692 companies for 3-Year EBITDA Growth Rate. This places Austco Healthcare in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Austco Healthcare's value of 35.70% is 335.4% above this benchmark. While the company's 10-year median is 18.40 vs. the industry median of 8.20, Austco Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austco Healthcare's current 3-Year EBITDA Growth Rate of 35.70% is 335.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Austco Healthcare and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austco Healthcare's current 3-Year EBITDA Growth Rate is 35.70%, which is 94% above median its own 10-year median of 18.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austco Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Austco Healthcare (ASX:AHC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.36, compared to a current price of A$0.23 — trading 37.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 35.70%, which is 94% above median its 10-year median of 18.40 and 335.4% above the Medical Devices & Instruments industry median of 8.20. Austco Healthcare's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Austco Healthcare (ASX:AHC), the current 3-Year EBITDA Growth Rate is 35.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austco Healthcare (ASX:AHC) Overvalued in 2026?
Based on GuruFocus' analysis, Austco Healthcare stock appears to be undervalued.
The current stock price of A$0.23 is trading 37.5% below its estimated GF Value™ of A$0.36.
GuruFocus considers Austco Healthcare to be Possible Value Trap.
Key valuation signals for ASX:AHC:
3-Year EBITDA Growth Rate: 35.70% (94% above median its 10-year median of 18.40)
GF Value™: A$0.36 vs. price of A$0.23 (37.5% below fair value)
Industry Position: 335.4% above the Medical Devices & Instruments median (#128 of 692)
No single metric tells the full story. See the ASX:AHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austco Healthcare Ltd engages in the development and provision of electronic communications and clinical management solutions. It offers Tacera, a nurse call, and healthcare communication system for healthcare professionals and patient. The group is segmented into four geographic regions consisting of Australia/New Zealand, Asia, Europe, and North America.
56GF Score
Get the complete analysis for ASX:AHC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AHC has been successfully added to your 
